HomeAI · summaries
Storia in 2 fonti
Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval
The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for treating adults with complicated urinary tract infections (cUTI)
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…
- ·
Zaynich's blockbuster potential lifts Wockhardt's long-term outlook
Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting…
- ·
thehindubusinessline.com
Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval
The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for treating adults with complicated urinary tract…
- ·
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?
Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company…